OX40 triggering as therapeutic vaccination therapy. a. Representative hematoxylin and eosin (H&E) staining of intracranial tumors with GL261 cells. Day 8 (small model) and Day 18 (large model). Scale bar, 1 mm. b. Treatment schedules for small and large model mice. c. Survival curves. OX86 s.c. small model mice (n = 6) vs. IgG s.c. (n = 8) small model mice (*P = 0.0004) or OX86 s.c. large model mice (n = 9) (P = 0.0009). OX86 s.c. large model mice vs. IgG s.c. (*P < 0.0001). s.c. lysate with OX86 i.p. (n = 6) did not prolong the survival of mice in large model. d. H&E staining of intracranial tumors with NSCL61 (Upper scale bar, 1 mm; lower, 400× magnification of boxed area, scale bar, 40 μm). e. Treatment schedules for NSCL61 models. f. Survival curves of NSCL61 models. OX86 s.c. model mice were associated with prolonged survival than IgG s.c. model mice (n = 10 each, *P < 0.0001).